Lee's Pharmaceutical Holdings Limited

As of June 30, 2023, Lee's Pharmaceutical Holdings Limited carries a market capitalization of 818.48M, placing it among publicly traded companies globally. Its enterprise value stands at 781.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lee's Pharmaceutical Holdings Limited's next confirmed earnings release is scheduled for March 30, 2027.

As of June 30, 2023, Lee's Pharmaceutical Holdings Limited has 588.84M shares outstanding.

These figures are as of June 30, 2023.

As of June 30, 2023, Lee's Pharmaceutical Holdings Limited maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2023.

Over the twelve months ended June 30, 2023, Lee's Pharmaceutical Holdings Limited recorded 9.18M in income tax expense.

As of the close on October 22, 2026, Lee's Pharmaceutical Holdings Limited's stock has declined approximately 45.73% over the past 52 weeks. The 50-day moving average sits at 1.17, while the 200-day moving average is 1.24.

As of June 30, 2023, Lee's Pharmaceutical Holdings Limited holds 161.52M in cash and equivalents against 202.19M in total debt, resulting in a net debt position of 24.73M. Total book value stands at 1.97B, with working capital of 2.10M providing operational flexibility.